2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinib
2021
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.
Pal S, Tangen C, Thompson I, Haas N, George D, Heng D, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason G, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara P. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Journal Of Clinical Oncology 2021, 39: 270-270. DOI: 10.1200/jco.2021.39.6_suppl.270.Peer-Reviewed Original ResearchMetastatic papillary renal cell carcinomaPapillary renal cell carcinomaProgression-free survivalMedian progression-free survivalEligible patientsPO QDPrior therapyOverall survivalAdverse eventsGrade 5 adverse eventsZubrod performance status 0Measurable metastatic diseasePerformance status 0Randomized phase IIRenal cell carcinomaMET kinase inhibitorType IMeaningful prolongationPo bidStatus 0Secondary endpointsMetastatic diseasePathologic reviewPFS eventsSystemic therapy